Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
Fiche publication
Date publication
juillet 2019
Journal
Journal of neuro-oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ETIENNE-SELLOUM Nelly, Pr NOEL Georges, Pr TAILLANDIER Luc, Dr LORGIS Véronique
Tous les auteurs :
Morisse MC, Etienne-Selloum N, Bello-Roufai D, Blonski M, Taillandier L, Lorgis V, Noël G, Ahle G, Durán-Peña A, Boone M, Chauffert B
Lien Pubmed
Résumé
Recurrence of glioblastoma (GB) occurs in most patients after standard concomitant temozolomide-based radiochemotherapy (CTRC). Bevacizumab (BV), an anti-VEGF antibody, has an effect on progression-free survival (PFS) but not on overall survival (OS). However, a small part of the patients experience a survival, longer than expected. This retrospective study aims to characterize long responder (LR) patients treated with BV for a first or second GBM recurrence.
Mots clés
Bevacizumab, Glioblastoma
Référence
J. Neurooncol.. 2019 Jul 19;: